Procept Biorobotics Corp PRCT
Image-guided robotic waterjet precision builds a durable clinical and economic position in urology where surgeon familiarity and outcome data compound adoption over decades.
Valuation holds this up; Optionality is the soft spot.
| Moat | 5.0 |
| Management | 4.0 |
| Valuation | 7.0 |
| Risk · 10 = lowest | 5.0 |
| Business model | 5.0 |
| Optionality | 4.0 |
The price needs 9.0% growth a year for ten years. The AI thinks 22.0% is achievable, at a 15.0% margin.
The +13% gap shows PRCT is undervalued, with achievable 22% growth well above the 9% required at 15% margin to justify the current price.
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. The company also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.
Write why this business works, set your own fair value, and let the briefing speak only when a rule you wrote is crossed.
Start the thirty days · no card